Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 ...

Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 ...

Novavax Inc (NVAX) outlines its strategic focus on partnerships and pipeline expansion while navigating revenue fluctuations ...

Novavax reported Q4 sales of $88.31 million, beating estimates despite a decline. The company shifts focus to partnerships ...

Novavax Inc. (NVAX) shares climbed over 1% in after-hours trading Thursday as the vaccine maker's revenue outlook and ...

Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.

Novavax (NVAX) reported a large fourth quarter sales decline Thursday — and said it no longer wants to be known simply as a ...

BTIG initiated coverage of Novavax (NVAX) with a Buy rating and $19 price target The company’s standalone COVID vaccine seems to be a ...

COVID-19 vaccines target emerging variants, offering improved protection. Learn about their effectiveness, timing, and safety ...

Novavax (NVAX) stock in focus as company beats Q4 revenue forecasts despite an 80% drop in product sales. Read more here.

NVAX reports encouraging fourth-quarter results. It completes the sale of its Czech Republic manufacturing unit to Novo ...

Novavax (NVAX) stock jumped today following the release of the vaccine maker’s Q4 2024 earnings report. That follows its diluted earnings per ...